IDH1 and acute myeloid leukemia: Ivosidenib (Tibsovo; Agios Pharmaceuticals, Inc, Cambridge, MA, USA), a small‐molecule inhibitor of mutated IDH1, was initially approved by the FDA in 2018 for adults with relapsed/refractory IDH1‐mutated AML.